ASCO 2023 | Top breast cancer abstracts at ASCO 2023: NATALEE and PHERGain

Yutaka Yamamoto, MD, PhD, Kumamoto University Hospital, Kumamoto, Japan, provides an overview of recently-presented updates in influential breast cancer trials including the Phase III NATALEE (NCT03701334) and the Phase II PHERGain (NCT03161353) trials. The NATALEE trial met its primary endpoint with a clinical meaningful benefit with ribociclib plus endocrine therapy in patients with early breast cancer, and the PHERGain trial demonstrated the utility of dual HER2 blockade in early breast cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.